COVID-19 remains in the spotlight of this week’s policy recap as Pfizer-BioNTech’s COVID-19 vaccine is granted full FDA approval. And CMS boosts reimbursement rates for COVID-19 vaccines...
This week’s policy update highlights the CDC’s new masking guidelines, triggered by the spread of the Delta variant. Meanwhile, long COVID was added to the list of qualifying disabilities...
CMS announced it will begin coverage determination investigations for the controversial Alzheimer’s drug, Aduhelm, while the drug’s approval process is also being investigated by the FDA....
Happy Tuesday! Folks on either coast of the United States are facing either record high temperatures or levels of rainfall. As is the case most times, meteorologists are the only ones satisfied.
FDA...
To improve access to COVID-19 testing and vaccination, FDA, CMS, and HHS are increasing vaccine supplies, vaccination sites, and funding. Meanwhile, HHS extended key reporting deadlines for the...
The approval by FDA of Biogen’s Alzheimer’s drug Aduhelm has led to the resignation of three committee members, citing disagreement with the department’s decision. The efficacy of the...
It’s been a busy week in healthcare, beginning with FDA’s approval of Biogen’s Alzheimer’s drug, Aduhelm, which continues to draw the ire of industry experts across the...
In an effort to reduce the US reliance on the global pharmaceutical supply chain, the Biden Administration accepted recommendations for improving the US supply chain. Meanwhile, the FDA approved a...
Happy Friday after a long short week of work. Many of us in the Northeast will be scrambling to the coast to get some sun following a bleak and dreary Memorial Day Weekend.
Press Ganey Gets OK from...
As the DOJ sets its eyes on COVID-19-related telefraud, CMS called for public comments on delaying value-based drug payment rules. Meanwhile, a new Senate bill proposes expanding VA mental health...
The Biden Administration announces additional funding for vaccination efforts as local vaccination campaigns are slated to push the United States to herd immunity. And HHS announces over one million...
The FDA remains busy as Johnson & Johnson vaccine review ends and cancer drug approval discussions commence. Meanwhile, HHS allocates funding to medically underserved health centers to improve...
HHS announced funding to support community-based organizations in their battle against COVID-19 and proposed changes to Title X to promote more equitable care delivery. Meanwhile, CMS delays...
